CD79
| CD79a molecule, immunoglobulin-associated alpha
| |
| Identifiers | |
| Symbol | CD79A |
| Alt. Symbols | IGA |
| Entrez | 973 |
| HUGO | 1698 |
| OMIM | 112205 |
| RefSeq | NM_001783 |
| UniProt | P11912 |
| Other data | |
| Locus | Chr. 19 q13.2 |
| CD79b molecule, immunoglobulin-associated beta
| |
| Identifiers | |
| Symbol | CD79B |
| Alt. Symbols | IGB |
| Entrez | 974 |
| HUGO | 1699 |
| OMIM | 147245 |
| RefSeq | NM_021602 |
| UniProt | P40259 |
| Other data | |
| Locus | Chr. 17 q23 |
CD79 is a transmembrane protein that forms a complex with the B-cell receptor (BCR) and generates a signal following recognition of antigen by the BCR. CD79 is composed of two distinct chains called CD79a and CD79b (formerly known as Ig-alpha and Ig-beta); these form a heterodimer on the surface of a B cell stabilized by disulphide bonding.[1] CD79a and CD79b are both members of the immunoglobulin superfamily. Human CD79a is encoded by the mb-1 gene that is located on chromosome 19, and CD79b is encoded by the B29 gene that located on chromosome 17.[1][2] Both CD79 chains contain an immunoreceptor tyrosine-based activation motif (ITAM) in their intracellular tails that they use to propogate a signal in a B cell, in a similar manner to CD3 generated signal tranduction observed during T cell receptor activation on T cells.[3]
References
- ↑ 1.0 1.1 Chu P, Arber D (2001). "CD79: a review". Appl Immunohistochem Mol Morphol 9 (2): 97-106. PMID 11396639.
- ↑ Van Noesel C, Brouns G, van Schijndel G, Bende R, Mason D, Borst J, van Lier R (1992). "Comparison of human B cell antigen receptor complexes: membrane-expressed forms of immunoglobulin (Ig)M, IgD, and IgG are associated with structurally related heterodimers". J Exp Med 175 (6): 1511-9. PMID 1375264.
- ↑ Müller B, Cooper L, Terhorst C (1995). "Interplay between the human TCR/CD3 epsilon and the B-cell antigen receptor associated Ig-beta (B29)". Immunol Lett 44 (2-3): 97-103. PMID 7541024.
External links
Proteins: clusters of differentiation (see also list of human clusters of differentiation) | |
|---|---|
| 1-50 | CD1 (CD1a-c, CD1d) - CD2 - CD3 - CD4 - CD5 - CD8 - CD9 - CD10 - CD11 (CD11a, CD11b, CD11c) - CD13 - CD14 - CD15 - CD16 - CD18 - CD19 - CD20 - CD21 - CD22 - CD23 - CD24 - CD25 - CD26 - CD27 - CD28 - CD29 - CD30 - CD31 - CD32 - CD33 - CD34 - CD35 - CD36 - CD37 -CD38 - CD40 - CD43 - CD44 - CD45 - CD46 - CD49 (CD49a, CD49b, CD49c, CD49d) |
| 51-100 | CD52 - CD53 - CD54 - CD55 - CD56 - CD58 - CD59 - CD61 - CD62 (CD62E, CD62L, CD62P) - CD63 - CD64 - CD66e - CD68 - CD70 - CD71 - CD72 - CD79 - CD80 - CD81 - CD82 - CD83 - CD86 - CD88 - CD89 - CD90 - CD94 - CD95 - CD97 - CD98 |
| 101-350 | CD103 - CD106 - CD114 - CD116 - CD117 - CD118 - CD120 - CD122 - CD130 - CD131 - CD132 - CD133 - CD134 - CD135 - CD137 - CD138 - CD141 - CD142 - CD143 - CD146 - CD147 - CD151 - CD152 - CD153 - CD154 - CD155 - CD162 - CD164 - CD169 - CD184 - CD206 - CD209 - CD257 - CD278 - CD281 - CD282 - CD283 - CD304 |
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies